With over a decade of experience in consulting, Sami has worked alongside leading global pharmaceutical and biotech companies, shaping commercial and medical strategies throughout the product lifecycle.

Sami has held leadership roles at Vynamic Consulting, EY-Parthenon (Ernst & Young Consulting), and Navigant Consulting, bringing a wealth of expertise in strategic decision-making.

He holds a D.Phil in Computational Chemistry from the University of Oxford and an M.Sc. in Drug Design from University College London.

Additionally, Sami has completed his Executive Education at MIT Sloan School of Management in AI and Business Strategy, further strengthening expertise at the intersection of science, business, and digital technology.

With 25 years of consulting experience, Peter has been a trusted partner to global pharmaceutical, med-tech, and health companies, helping them navigate every aspect of their business.

His expertise spans the full value chain, ensuring organizations not only meet but exceed their targets.

Peter holds an MBA from the University of Chicago Booth School of Business and a B.Sc. in Environmental Sciences and Biology from McMaster University, combining strategic business acumen with a strong scientific foundation.

Rafiq is a seasoned leader in the global pharmaceutical industry, with a distinguished career that includes senior roles in ophthalmology at Bayer and Novartis.

As SVP and Global Head of Ophthalmology at Bayer, Rafiq played a pivotal role in driving the success of Eylea®, leading its growth from launch to over $2.5 billion in just five years and spearheading its expansion into five indications within three years.

Rafiq's academic foundation includes medical training at Guy's and St Thomas' (University of London) and executive education at Harvard Business School, equipping him with a unique blend of clinical expertise and strategic business leadership.

Kelvin has spent over a decade shaping Data Science and AI strategies for leading European financial institutions, most recently as Senior Vice President at Houlihan Lokey.

A published author in Data Science, Kelvin is a thought leader in AI-driven innovation, applying cutting-edge techniques across industries and pushing the boundaries of AI in financial modelling.

Kelvin holds a D.Phil in Computational Chemistry from the University of Oxford and completed and completed post-doctoral training under Prof. Rob Paton at Oxford, bringing a strong scientific foundation to his work at the intersection of AI, finance, and technology.

Ali brings extensive medical expertise from both the healthcare and pharmaceutical industries, with a deep focus on oncology. Most recently, he served as a Global Medical Director at Roche, where he played a key role in shaping medical strategy and innovation.

With a unique perspective that bridges clinical and industry insights, Ali helps uncover new opportunities for growth and impact.

Ali holds qualifications in Clinical Pharmacy Practice from University College London and an M.Pharm from University of Portsmouth, combining scientific expertise with a strategic approach to healthcare.